Revisiting asthma therapeutics: focus on WNT signal transduction

Citations of this article
Mendeley users who have this article in their library.


Asthma is a complex disease of the airways that develops as a consequence of both genetic and environmental factors. This interaction has highlighted genes important in early life, particularly those that control lung development, such as the Wingless/Integrase-1 (WNT) signalling pathway. Although aberrant WNT signalling is involved with an array of human conditions, it has received little attention within the context of asthma. Yet it is highly relevant, driving events involved with inflammation, airway remodelling, and airway hyper-responsiveness (AHR). In this review, we revisit asthma therapeutics by examining whether WNT signalling is a valid therapeutic target for asthma. WNT signalling is a relevant, yet underappreciated pathway in asthma. Recent insights into the pathology of asthma have highlighted this pathway as a potential novel therapeutic point of intervention. With this in mind, we attempt to answer the question: is WNT signalling a valid target for asthma therapy?




Koopmans, T., & Gosens, R. (2018, January 1). Revisiting asthma therapeutics: focus on WNT signal transduction. Drug Discovery Today. Elsevier Ltd.

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free